|
29. January, 2013 QPS and Amorfix to collaborate on Alzheimer's Disease Project TORONTO, Ontario – January 29, 2013 – Amorfix Life Sciences Ltd. announced today that the Company will collaborate with QPS Holdings, LLC, a leading global provider of discovery and development services for pharmaceutical, biotechnology and medical device companies, to further develop and validate its proprietary Alzheimer’s disease diagnostic EP-AD assay. |
|
|
29. August, 2012 QPS acquires JSW Life Sciences, largest independent Contract Research Organisation in Austria August 29, 2012; Newark, Delaware, USA and Grambach, Austria; QPS, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced the acquisition of a majority interest in JSW Life Sciences GmbH. JSW provides preclinical and clinical Phase II – IV drug development services to pharmaceutical and biotech companies worldwide, and will be known as QPS JSW. |
![]() |
|
JSW Life Sciences
Received AAALAC Full Accreditation Being the third institution in Austria, JSW Life Sciences received full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International off the cuff without further requirements. |
|
|
14. September, 2011 Winner of the Styrian Fast Forward Award 2011 JSW Life Sciences GmbH with „ New cell cultures as an alternative to animal experiments in drug discovery and development“ The company is principally involved in drug development for treatment of Alzheimer and Parkinson disease. Before a new drug is tested in humans, it´s effects have to be proven in animal tests or cell cultures, although tests with living animals become less because of moral and monetary reasons. The new developed cell culture model shows significant comparability with existing conditions of an Alzheimer or Parkinson effected human brain and therefore differs from other models. With this new model the probability of selecting the right substances for the ongoing drug development rises, by the chance of reducing the developing period. The model is soon to be published. |
|



